Truist raises Edwards Lifesciences stock price target on TAVR growth

EW is still one of the cleaner ways to own a durable medtech growth compounder, but the market is now paying for a fairly visible path rather than a hidden one. The important read-through is not just that execution is good; it is that the competitive gap versus MDT may widen again before new-product catalysts arrive, because once share loss starts to show up in a procedure franchise it tends to be sticky and self-reinforcing through hospital workflow, physician preference, and training effects.

The second-order issue is valuation asymmetry. At this size, the stock needs either a faster-than-expected inflection in the next growth leg or multiple support from continued rate stability; otherwise, any quarter that is merely in-line could compress the premium quickly. The next 2-3 quarters matter less for earnings revisions than for whether management can prove that the current growth rate is not a peak-ish plateau ahead of the TMTT catalyst window.

From a competitive standpoint, MDT looks like the incremental loser even if the near-term financial damage is still modest. The risk is that share leakage in TAVR becomes a broader signal that interventional cardiovascular franchises can lose compounding advantages faster than consensus models assume, which would pressure sentiment not just in MDT but in adjacent large-cap device names with similar “defend-and-extend” narratives.

The contrarian view is that the market may be underestimating how much of the good news is already embedded in expectations after a strong beat and repeated guide-upward revisions. If TMTT is the real upside call option, investors should be careful not to pay full premium today for a catalyst that is still 12-24 months away and could be partially offset by margin normalization or tougher comps.